In this episode, we discuss two new agents (valbenazine and deutetrabenazine) -- the first of their kind to receive FDA approval to manage tardive dyskinesia most commonly associated with antipsychotic use.
Want to check another podcast?
Enter the RSS feed of a podcast, and see all of their public statistics.
